Dr. Vince Clinical Research Expands Leadership in Renal and Hepatic Clinical Pharmacology Studies

Harry Alcorn, PharmD joins as Senior Vice President of Renal and Hepatic Research to advance scientific and operational expertise.

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research (DVCR), a leading contract research organization (CRO), today announced the appointment of Harry Alcorn, PharmD, as Senior Vice President of Renal and Hepatic Research. In this role, Alcorn will provide scientific and operational oversight for renal and hepatic impairment studies.

Alcorn brings more than 30 years of early phase clinical research experience, including leadership of Phase I research units and global clinical development programs. Most recently, he founded and led a Phase I clinical research unit focused on renal and hepatic studies, overseeing both clinical and operational execution. He has also held senior leadership roles in clinical operations and previously led one of the first U.S. networks of Phase I renal research sites. Alcorn has authored more than 50 clinical research protocols and has served as an investigator on over 300 studies.

“Harry Alcorn’s addition to the DVCR team further strengthens our industry leading expertise in the conduct of these complex clinical trials that are often required for NDA submissions,” said Bradley Vince, DO, CEO and Chief Medical Officer of Dr. Vince Clinical Research.

Alcorn’s appointment reflects DVCR’s continued focus on supporting clinical pharmacology studies from First-in-Human through NDA submission. Successfully conducting renal and hepatic impairment studies requires a deep understanding of how inclusion and exclusion criteria impact timelines, costs and operational success. Expertise in protocol design plays a critical role in studies involving these specialized patient populations. His work in establishing and collaborating with sites specializing in renal and hepatic impairment trials will also enhance DVCR’s multi-site capabilities.

“I’m thrilled to contribute to the evolution of clinical research while supporting our sponsors and sites in advancing patient-focused studies that address the unique needs of each population,” stated Alcorn. “These studies require a high level of precision in patient selection, study design and regulatory strategy, and I look forward to working with the team to support programs through NDA submission.”

About Dr. Vince Clinical Research

Dr. Vince Clinical Research (DVCR) is a full-service contract research organization (CRO) specializing in early phase trials in both healthy normal volunteers and patient populations across a wide range of trial designs and therapeutic areas such as neuroscience, substance use disorders, dermatology, immunology, cardiometabolic disorders and many others. CRO services include project management, data management, biostatistics, statistical programming, PK/PD analysis and modeling, clinical and medical monitoring, medical writing as well as site feasibility, management and central laboratory services for multi-site trials with our global network of site partners.

Additionally, DVCR operates one of the most innovative and technologically advanced clinical pharmacology units in the world with 100 beds for overnight confinement, a cGMP compliant pharmacy as well as luxurious amenities to support diverse study participant recruitment and retention. By leveraging technology and one of the country’s most experienced leadership teams in early clinical development, DVCR provides Smarter Faster Data® to its biopharmaceutical clients.

For more information, visit: https://drvince.com/cro
Connect with DVCR on LinkedIn and YouTube